$SINT Cashflow Statement | Understand Stock

$SINT

$1.71 +$0.15 (9.62%) Close

$SINT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flow from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Amortization of right of use asset
Amortization of intangible assets
Non-cash interest income
Non-cash interest expense
Loss on disposal of subsidiary
Impairment of Armor
Stock based compensation – Employee
Stock based compensation – Non-employee
Change in fair value of derivative liabilities
Loss (gain) on disposal of equipment
Non-cash other income – forgiveness of loans
Bad debt expense (recoveries)
Changes in operating assets and liabilities:
Account and other receivables
Prepaid expenses and other assets
Inventories
Accounts payable and accrued liabilities
Other liabilities
Payments on operating lease liability

Net cash used in operating activities
Cash flows from investing activities
Purchase of property and equipment
Proceeds from note receivable, net of imputed interest
Disposal of property and equipment, net of cash received
Proceeds from the sale of property and equipment
Cash acquired in acquisition (see Note 2)
Proceeds from acquisition of Sinaptic Surgical
Proceeds from notes receivable, net of imputed interest
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from issuance of warrant derivative liabilities
Proceeds from issuance of preferred stock recorded as derivative liabilities, net
Proceeds from issuance of common stock and prefunded warrants, net of cash fees
Proceeds from issuance of preferred stock, net
Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities)
Proceeds from issuance of common stock in connection with ATM, net of fees
Proceeds from issuance of warrants in connection with exercise of warrants
Purchase of common stock into treasury
Proceeds from issuance of common stock in connection with exercise of warrants
Redemption of preferred stock Series E
Principal payment on debt
Proceeds from issuance of debt
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Noncash investing and financing activities
Reduction of derivative liability upon exercise of warrants
Right of use asset for amended lease liability – increase
Right-of-use assets and assumption of operating lease liability
Extinguishment of derivative liabilities through exercise of warrants
Issuance of common stock for the cashless exercise of warrants
Issuance of prefunded warrants
Deemed dividend related to warrant inducement and issuance of warrants
Right of use asset for amended lease liability – decrease
Acquisition of subsidiary through assumption of debt (see Note 2)
Conversion of preferred stock to common stock
Debt issued for prepaid insurance
Agent warrant offering cost allocated to equity

Supplemental cash flow information
Cash paid for interest

Comments